CIDRAP newsletters options
The addition of the antibiotic azithromycin to seasonal malaria chemoprevention (SMC) was associated with an increase in azithromycin-resistant serotypes of Streptococcus pneumoniae in children in Burkina Faso, researchers reported yesterday in The American Journal of Tropical Medicine and Hygiene.
The ban on using colistin for growth promotion is tied to reduced MCR-1 in both animals and people.
Yesterday, 75% of cases were in 10 nations, mostly in the Americas and South Asia.
Keeping infected moms in rooms separate from their babies is one approach, but with breast milk options.
New data show that 600 frontline US health workers have died from COVID-19.
Twelve cases have now been reported in a new Ebola outbreak in northwestern Democratic Republic of the Congo (DRC), up from eight last week. The World Health Organization (WHO) confirmed in an email today that there are 12 cases in Equateur province, which includes 9 confirmed and 3 probable infections. Five deaths have been reported.
Implementation of behavioral "nudges" targeting non–guideline-concordant antibiotic prescribing helped reduce inappropriate prescribing for respiratory tract infections at three California urgent care centers (UCCs), researchers reported last week in Open Forum Infectious Diseases.
"I do think there is a potential, unfortunately, for this to be a seeding event," says CDC Director Redfield.
Antibiotic therapy with CRP-guided duration or fixed 7-day duration were found to be non-inferior to 14 days of antibiotics.
UK researchers stop a large hydroxychloroquine trial after no benefit was found in hospitalized patients.
Two studies in France highlight the multisystem inflammatory disorder.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
A study yesterday in The Lancet presents the clinical findings of autopsies conducted on six German patients (four men and two women, aged 58 to 82 years) who died from COVID-19 in April. All six had evidence of extensive brain pathologies at the time of death.
Each patient had severe viral pneumonia caused by COVID-19 and required mechanical intubation or extracorporeal membrane oxygenation.
Pharmaceutical company Merck announced today that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the antibacterial combination drug Recarbrio to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by gram-negative pathogens.
The drug did not show effectiveness for postexposure prevention of COVID-19.
Hot spots include Brazil, Mexico, Peru, India, and Iran, and global deaths are nearing 400,000.
The company that obtained and analyzed study data would not comply with an audit, the study authors say.
The NIH director says some candidates will be ready for large-scale testing as early as July.
Though no effect was found, the study was stopped early because of low enrollment.
The World Health Organization (WHO) this week published a technical brief on water, sanitation, hygiene (WASH), and wastewater management to prevent infections and curb the spread of antimicrobial resistance (AMR).
